Treatment‐related mortality in relapsed childhood acute lymphoblastic leukemia

Abstract

Fatal treatment complications contribute significantly to the poor overall survival after relapse. Implementation of novel therapies with reduced toxicity and aggressive supportive care management are important to improve survival in relapsed childhood ALL.